Swedish Orphan Biovitrum AB (publ) (BIOVF) Comparison with companies in other sectors?

Swedish Orphan Biovitrum AB (publ) has a share price of 344.61M. You can analyze Swedish Orphan Biovitrum AB (publ) (BIOVF) competitors across different market sectors through stock heatmaps.

What are BIOVF's NET and operating margins?

Swedish Orphan Biovitrum AB (publ) (BIOVF) operating margin is around 0.22, and net profit margin is approximately 0.15 as of the latest reports.

In what way does BIOVF's earnings per share (EPS) trend reflect its financial momentum?

Swedish Orphan Biovitrum AB (publ) (BIOVF) EPS is 1.33 (If EPS value is positive, then “signals consistent profit growth” if Negative then “signals consistent loss”). This metric is also critical in assessing valuation metrics like the P/E ratio for Swedish Orphan Biovitrum AB (publ) is 22.40, and the company’s ability to reinvest or distribute profits.

What does a high ROE mean for Swedish Orphan Biovitrum AB (publ)?

A high ROE suggests efficient use of shareholder equity to generate profit. It often signals strong management and profitability.

How do I know if AAPL is overvalued or undervalued?

Check valuation ratios for Swedish Orphan Biovitrum AB (publ) like P/E which is 24.59, P/B which is 2.50, and PEG which is 1.47. Compare them with sector averages to evaluate if the stock is priced fairly.

Swedish Orphan Biovitrum AB (publ)

BIOVF•PNK

Healthcare

Drug Manufacturers - Specialty & Generic

$29.79

$0.00(0.00%)

Fundamental Analysis of Swedish Orphan Biovitrum AB (publ) (BIOVF)

Comprehensive financial metrics and ratios analysis

EPS (TTM)

$1.33

P/E Ratio

22.40

ROE

0.10%

Net Margin

0.15%

Key Financial Metrices

Valuation Metrics

4 metrics

Market CapTotal market value of outstanding shares

$10.27B

Shares OutstandingTotal number of shares issued

$344.61M

Book Value/ShareNet worth per share

$113.66

Revenue/ShareAnnual revenue per share

$76.39

Profitability Metrics

6 metrics

EPS (TTM)Earnings per share trailing twelve months

$1.33

Net MarginNet income as percentage of revenue

15.09%

Operating MarginOperating income as percentage of revenue

21.72%

ROEReturn on shareholders' equity

10.37%

ROAReturn on total assets

5.65%

ROCEReturn on capital employed

9.80%

Cash Flow Metrics

3 metrics

Free Cash Flow/ShareCash generated per share after capex

$15.51

Cash/ShareCash and equivalents per share

$2.90

FCF YieldFree cash flow as percentage of market cap

5.45%

Dividend Metrics

2 metrics

Dividend/ShareAnnual dividend payment per share

Dividend YieldAnnual dividend as percentage of stock price

Financial Ratios Analysis data is not available for BIOVFFinancial Ratios Analysis details for BIOVF are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Sector Benchmarking data is not available for BIOVFSector Benchmarking details for BIOVF are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Understanding Fundamental Analysis for Swedish Orphan Biovitrum AB (publ) Investment Decisions

What is Fundamental Analysis?

Fundamental analysis is a method used to assess the intrinsic value of Swedish Orphan Biovitrum AB (publ). Using financial reports, management structure, competitive position, and market environment, investors can determine whether the stock is undervalued or overvalued. This analysis helps investors like you make more informed investment decisions, taking into account Swedish Orphan Biovitrum AB (publ)'s unique business strengths and challenges.

Key Financial Metrics for Swedish Orphan Biovitrum AB (publ)

For Swedish Orphan Biovitrum AB (publ), essential financial indicators include EPS 1.33, PE 22.40, and ROE 0.10. These key ratios reveal insights into Swedish Orphan Biovitrum AB (publ)'s profitability, valuation, and operational health. Understanding these metrics enables you to compare Swedish Orphan Biovitrum AB (publ) with its industry peers and decide whether it presents a viable investment opportunity.

Profitability and Operational Efficiency of Swedish Orphan Biovitrum AB (publ)

Metrics like Net Margin 15.09% and ROA 5.65% shed light on how well Swedish Orphan Biovitrum AB (publ) is generating profits. A high profitability ratio often indicates strong management and a solid business model, which are essential for long-term growth. These metrics are crucial in assessing whether Swedish Orphan Biovitrum AB (publ) can sustain its operations and continue growing in the future.

Valuation and Market Position of Swedish Orphan Biovitrum AB (publ)

Using ratios such as P/B Ratio 2.50 and PEG Ratio 1.47, investors can assess whether Swedish Orphan Biovitrum AB (publ) is appropriately valued based on its financials and growth potential. These figures, combined with Swedish Orphan Biovitrum AB (publ)'s market capitalization, give insight into its competitive positioning and investor expectations, helping you make informed decisions on pricing and value.

Financial Health and Risk Assessment for Swedish Orphan Biovitrum AB (publ)

Financial health indicators, such as Debt/Equity Ratio 0.36 and Cash Flow $15.51, provide a snapshot of Swedish Orphan Biovitrum AB (publ)'s ability to meet financial obligations and handle economic setbacks. A company with a strong balance sheet and solid cash flow, like Swedish Orphan Biovitrum AB (publ), is more likely to weather financial storms, making it a safer investment.

Long-Term Investment Strategy for Swedish Orphan Biovitrum AB (publ)

Investing in Swedish Orphan Biovitrum AB (publ) based on fundamental analysis emphasizes long-term business growth rather than short-term market trends. Investors looking at Swedish Orphan Biovitrum AB (publ) focus on its solid financial performance, industry standing, and competitive advantages, all of which suggest sustainable growth and the potential for steady returns over time.

Fundamental Analysis FAQ

;